Showing results (61-70 of 101) with videos related to

Sort By:
Pageof 11
Clinical Genitourinary Cancer|January 22, 2013
Response evaluation criteria in solid tumors response of the primary lesion in metastatic renal cell carcinomas treated with sunitinib: does the primary lesion have to be regarded as a target lesion?Inkeun Park, Kwonoh Park, Seongjoon Park, et al.
Journal of Cancer Research and Clinical Oncology|January 13, 2012
Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk featuresJae-Lyun Lee, Inkeun Park, Kwonoh Park, et al.
Current Problems in Cancer|September 23, 2024
Four versus six cycles of platinum-based chemotherapy for advanced Urothelial carcinoma in the era of immune checkpoint inhibitors: A retrospective cohort study (FOCUS, KCSG-GU23-08)Kwonoh Park, Eo Jin Kim, Jin Young Kim, et al.
Cancer Chemotherapy and Pharmacology|June 25, 2009
Phase I/II and pharmacokinetic study of S-1 and oxaliplatin in previously untreated advanced gastric cancerInkeun Park, Jae-Lyun Lee, Min-Hee Ryu, et al.
Investigational New Drugs|August 23, 2014
Epidermal growth factor receptor (EGFR) exon 20 mutations in non-small-cell lung cancer and resistance to EGFR-tyrosine kinase inhibitorsHyun Sun Woo, Hee Kyung Ahn, Ha Yeon Lee, et al.
Cancer Research and Treatment|April 2, 2016
Prognostic Factors for Risk Stratification of Patients with Recurrent or Metastatic Pancreatic Adenocarcinoma Who Were Treated with Gemcitabine-Based ChemotherapyInkeun Park, Seung Joon Choi, Young Saing Kim, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|April 17, 2014
Clinical significance of Ki-67 and p53 expression in curatively resected non-small cell lung cancerHee Kyung Ahn, Minkyu Jung, Seung-Yeon Ha, et al.
Cancer Chemotherapy and Pharmacology|November 9, 2013
A randomized phase II study of weekly docetaxel/cisplatin versus weekly docetaxel/oxaliplatin as first-line therapy for patients with advanced gastric cancerYoung Saing Kim, Sun Jin Sym, Se Hoon Park, et al.
American Journal of Clinical Oncology|January 6, 2022
Efficacy and Safety of Trastuzumab Biosimilar (CT-P6) Compared With Reference Trastuzumab in Patients With HER2-positive Advanced Gastric Cancer: A Retrospective AnalysisJoo-Hwan Park, Ja Hyun Yeo, Young Saing Kim, et al.
Cancer Chemotherapy and Pharmacology|August 7, 2012
Safety and feasibility of adjuvant chemotherapy with S-1 for Korean patients with curatively resected advanced gastric cancerJae Ho Jeong, Min-Hee Ryu, Baek-Yeol Ryoo, et al.
Pageof 11